Payment overview · 2025
General Payments
$1,873.41
87 reported records · 22 companies
Healthcare provider profile · identity verified
Jasjit Walia, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · ELIZABETH, NJ · NPI 1477573814
Verified facts
What the public records show
CMS Open Payments records show Jasjit Walia, M.D received $1,873.41 in general payments during 2025 across 87 reported records.
Abbott Laboratories accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Verquvo, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 610 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 251 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 610 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Nurtec Odt by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $296.79 | 15.8% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $256.97 | 13.7% | 11 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $210.58 | 11.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $185.49 | 9.9% | 12 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $138.99 | 7.4% | 9 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $120.89 | 6.5% | 8 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $116.46 | 6.2% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.77 | 4.3% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$73.72 | 3.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.45 | 2.9% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.33 | 2.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.78 | 2.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.19 | 2.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.70 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.83 | 1.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.06 | 1.7% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $28.12 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.70 | 1.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $19.23 | 1.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.44 | 1.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.84 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $9.08 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,662.83 | 86 |
| Debt forgiveness | $210.58 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $207.10 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $182.96 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $138.99 | 9 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $116.46 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $109.72 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $104.84 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $80.77 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.65 | 5 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $73.72 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.87 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.33 | 3 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $46.84 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $43.23 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.78 | 3 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.73 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.55 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $28.12 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| JOT DX Normalized: jot dx |
Device | Abbott Laboratories | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.91 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $9.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 610 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 224 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 356 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 349 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 251 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
106 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
224 | 58 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
610 | 194 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
251 | 89 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
356 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 26 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
137 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
349 | 80 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
610 | 194 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1700 | 585 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1208 | 456 |
| Furosemide | Furosemide | 820 | 282 |
| Pantoprazole Sodium | Pantoprazole Sodium | 814 | 305 |
| Clopidogrel | Clopidogrel Bisulfate | 739 | 250 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 705 | 276 |
| Escitalopram Oxalate | Escitalopram Oxalate | 658 | 251 |
| Losartan Potassium | Losartan Potassium | 658 | 251 |
| Eliquis | Apixaban | 610 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 542 | 163 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 528 | 207 |
| Montelukast Sodium | Montelukast Sodium | 513 | 208 |
| Amlodipine Besylate | Amlodipine Besylate | 494 | 202 |
| Potassium Chloride | Potassium Chloride | 479 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 456 | 185 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 384 | 170 |
| Gabapentin | Gabapentin | 382 | 156 |
| Mounjaro | Tirzepatide | 356 | 72 |
| Metformin Hcl | Metformin Hcl | 353 | 152 |
| Ozempic | Semaglutide | 349 | 80 |
| Carvedilol | Carvedilol | 309 | 109 |
| Fluticasone Propionate | Fluticasone Propionate | 257 | 106 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 251 | 89 |
| Omeprazole | Omeprazole | 248 | 110 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 242 | 85 |
| Simvastatin | Simvastatin | 232 | 80 |
| Farxiga | Dapagliflozin Propanediol | 224 | 58 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 202 | 72 |
| Mirtazapine | Mirtazapine | 197 | 76 |
| Famotidine | Famotidine | 182 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 74 |
| Allopurinol | Allopurinol | 177 | 62 |
| Warfarin Sodium | Warfarin Sodium | 177 | 46 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 176 | 60 |
| Metformin Hcl Er | Metformin Hcl | 152 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 68 |
| Naproxen | Naproxen | 147 | 82 |
| Entresto | Sacubitril/Valsartan | 137 | 40 |
| Jardiance | Empagliflozin | 129 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 43 |
| Fenofibrate | Fenofibrate | 123 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 120 | 46 |
| Ezetimibe | Ezetimibe | 120 | 49 |
| Xarelto | Rivaroxaban | 120 | 34 |
| Meloxicam | Meloxicam | 112 | 56 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 111 | 46 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 108 | 38 |
| Brilinta | Ticagrelor | 106 | 35 |
| Linzess | Linaclotide | 102 | 32 |
| Trazodone Hcl | Trazodone Hcl | 102 | 48 |
| Azithromycin | Azithromycin | 99 | 77 |
| Digoxin | Digoxin | 99 | 32 |
| Bupropion Xl | Bupropion Hcl | 95 | 35 |
| Amitriptyline Hcl | Amitriptyline Hcl | 93 | 36 |
| Sertraline Hcl | Sertraline Hcl | 92 | 35 |
| Lisinopril | Lisinopril | 88 | 44 |
| Valsartan | Valsartan | 88 | 32 |
| Glipizide Er | Glipizide | 85 | 33 |
| Januvia | Sitagliptin Phosphate | 84 | 33 |
| Nitroglycerin | Nitroglycerin | 83 | 47 |
| Trulicity | Dulaglutide | 79 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 76 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 32 |
| Clobetasol Propionate | Clobetasol Propionate | 70 | 25 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 68 | 22 |
| Atenolol | Atenolol | 68 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 67 | 26 |
| Donepezil Hcl | Donepezil Hcl | 64 | 28 |
| Ammonium Lactate | Ammonium Lactate | 63 | 26 |
| Cilostazol | Cilostazol | 63 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 27 |
| Alendronate Sodium | Alendronate Sodium | 61 | 28 |
| Spironolactone | Spironolactone | 61 | 25 |
| Vascepa | Icosapent Ethyl | 61 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 29 |
| Lidocaine | Lidocaine | 59 | 27 |
| Meclizine Hcl | Meclizine Hcl | 59 | 33 |
| Glimepiride | Glimepiride | 58 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 57 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 23 |
| Alprazolam | Alprazolam | 56 | 33 |
| Fenofibrate | Fenofibrate,micronized | 56 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | 14 |
| Finasteride | Finasteride | 49 | 21 |
| Rizatriptan | Rizatriptan Benzoate | 49 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 15 |
| Celecoxib | Celecoxib | 43 | 17 |
| Labetalol Hcl | Labetalol Hcl | 42 | 14 |
| Folic Acid | Folic Acid | 41 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 39 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 14 |
| Acebutolol Hcl | Acebutolol Hcl | 37 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Tradjenta | Linagliptin | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | 15 |
| Sucralfate | Sucralfate | 35 | 14 |
| Nurtec Odt | Rimegepant Sulfate | 34 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | 15 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 31 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | 16 |
| Glipizide | Glipizide | 30 | 11 |
| Ibuprofen | Ibuprofen | 30 | 16 |
| Telmisartan | Telmisartan | 30 | 12 |
| Risperidone | Risperidone | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 14 |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Ondansetron Odt | Ondansetron | 24 | 12 |
| Colchicine | Colchicine | 23 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 20 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 13 |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Ofloxacin | Ofloxacin | 19 | 16 |
| Primidone | Primidone | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 15 |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | 11 |
| Propafenone Hcl | Propafenone Hcl | 17 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Verquvo | Vericiguat | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Keppra | Levetiracetam | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,873.41 · 87 records | Abbott Laboratories | AREXVY, AVEIR, Auvelity, BREZTRI, Barostim Neo System, CAMZYOS, CAPVAXIVE, CDS - MCT/CEM Monitoring, ELIQUIS, FARXIGA, FFRct, FREESTYLE LIBRE 3, GALLANT, Hillrom - Carnation Ambulatory Monitor, JARDIANCE, JOT DX, Kerendia, Korlym, LEQVIO, MINIMED 780G, MITRACLIP, MOUNJARO, Ozempic, REPATHA, Rybelsus, SHINGRIX, Saxenda, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, Wegovy, XIFAXAN, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error